Anti-obesity drugs for weight reduction;Gewichtsreduktion mittels pharmakotherapie

Internist

Volumn 44, Issue 3, 2003, Pages 359-366

  Wirth, A ^a  

^a Teutoburger Wald Klinik   (Germany)

Author keywords

Obesity; Orlistat; Risk factors; Sibutramine; Weight loss

Indexed keywords

SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTICLE; BODY FAT; DRUG EFFECT; ENERGY EXPENDITURE; ENERGY TRANSFER; HUMAN; LIFESTYLE; MORBIDITY; OBESITY; QUALITY OF LIFE; RISK FACTOR; SATIETY; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0037353930     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-0864-1     Document Type: Article

References (26)

1. Anderson JW, Konz EC, Frederich RC, Wood CL (2001) Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 74: 579-584
2. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E (1999) Long-term maintenance of weight loss after a very-low-caloric diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106: 179-184
3. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the STOP-NIDDM Trial Research Group (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359: 2072-2077
4. Colditz GA (1999) Economic costs of obesity and inactivity. Med Sci Sports Exerc 31: 663-667
5. Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. N Engl J Med 346: 393-403
6. Hauner H, Meier M, Wendland G, Lauterbach K and the S.A.T. study group (2002) Weight reduction by sibutramine in obese subjects in primary care medicine: the S.A.T. study. (submitted)
7. Hazenberg BP (2000) Randomized, double-blind, placebo-controlled multicenter study of sibutramine in obese hyptertensive patients. Cardiology 94: 152-158
8. Heal DJ, Prow MR, Jackson HC, Martin KF, Cheetham SC (1998) Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes 22 (Suppl): S18-S28
9. Hollander PA, St. Elbein C, Hirsch IB et al. (1998) Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 21: 1288-1294
10. James WP, Astrup A, Hilsted J et al. for the STORM Group (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 356: 2119-2125
11. Kelley DE, Hill J, Bray GA, Miles J, Sunyer FXP, Hollander P, Klein S (2002) Clinical efficiacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 25: 1033-1040
12. Lean MEJ (1997) Sibutramine - a review of clinical efficacy. Int J Obes 21: 116-123
13. Sarlio-Lähteenkorva A, Rissanen A, Kaprio J (2000) A descriptive study of weight loss maintenance: 6 and 15 year follow-up of initially overweight adults. Int J Obes 24: 116-125
14. Scholze J (2002) Adipositasbehandlung mit Sibutramin unter Praxisbedingungen. Dtsch Med Wochenschr 127: 606-610
15. Sharma AM, Golay A (2002) Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 20: 1873-1878
16. Sjöström L, Rissanen A, Andersen T et al. for the European Multicentre Study Group (1998) Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352: 167-173
17. Sjöström L (2002) Intervenire necesse est. Int J Obes 26 (Suppl): 53
18. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 244: 1343-1350
19. Van Gaal LF, Wauters MA, Pfeiffer FW, De Leeuw IH (1998) Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int J Obes 22 (Suppl): 538-540
20. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH (1995) Weight, weight chance, an coronary heart disease in women. Risk within the "normal" weight range. JAMA 273: 461-465
21. Wirth A, Platon J (2001) Effect of orlistat on body weight and co-morbidities in clinical practice: The XXL-Primary Health Care Observational Trial. Int J Obesity 25: 788 (abstract)
22. Wirth A, Krause J (2001) Long-term weight loss with sibutramine. A randomized controlled trial. JAMA 286: 1331-1339
23. Wirth A (2003) Adipositas-Fibel. Spfinger, Heidelberg Berlin New York, 5 181
24. Yanovski SZ, Yanovski JA (2002) Obesity. N Engl J Med 346: 591-602
25. Zannad F, Gille B, Grentzinger A et al. (2002) Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 144: 508-515
26. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptmann JB, Patel IH (1994) Retrospective population-based analysis of the dose-response (fetal fat excretion) relationship of orlistad in normal and obese volunteers. Clin Pharmacol Ther 56: 82-85